AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06375967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct > 18mm.~* DPPS size: 7Fr x 3-7cm.
Study NCT06185543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC
Description: Ciprofloxacin and celecoxib combination extended release formulation
Study NCT06185543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matches active drug in size, color and taste
Study NCT06474611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient nudge
Description: Patient receives an electronic or paper letter 'nudge' to talk to dr about LCS.
Study NCT04762589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001
Description: RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 5 months
Study NCT04762589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
Study NCT04876742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beer
Description: As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment.
Study NCT04876742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
Study NCT05271292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles
Study NCT05469399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment).
Study NCT05469399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment).
Study NCT05030545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
Study NCT05159869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: User-Led Meaningful Activity Plan
Description: The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
Study NCT05159869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: User-Led Meaningful Activity Plan
Description: The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
Study NCT05913765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air cleaner
Description: Austin Air Healthmate air cleaner with or without standard filter
Study NCT05913765 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Air cleaner
Description: Austin Air Healthmate air cleaner with or without standard filter
Study NCT04977726 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: STRIVE curriculum
Description: STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
Study NCT04977726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE curriculum
Description: STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
Study NCT06215677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
Study NCT05621031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body Vibration
Description: Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
Study NCT05621031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Therapy
Description: Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
Study NCT05621031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual Therapy
Description: Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
Study NCT05621031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo whole body vibration
Description: Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
Study NCT05353673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
Study NCT05353673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.
Study NCT05353673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.
Study NCT05318079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Gaming
Description: Peer-to-peer gaming.
Study NCT05612165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation(tDCS)
Description: The tDCS intervention was conducted for 20 minutes(2000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
Study NCT05612165 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation(sham tDCS)
Description: The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
Study NCT06001489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 360-degree Virtual Reality Patient Tour
Description: A 360-degree video that encompasses the entire clinical pathway. Patients are able to familiarize themselves with the hospital settings (nursery ward, operating room, intensive care unit).
Study NCT06001489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State Trait Anxiety Inventory
Description: Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
Study NCT06001489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: State Trait Anxiety Inventory
Description: Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
Study NCT06001489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Amsterdam Preoperative Anxiety and Information Scale
Description: This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
Study NCT06001489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amsterdam Preoperative Anxiety and Information Scale
Description: This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
Study NCT04371653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: administration orally
Study NCT04371653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration orally placebo
Study NCT05472948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib will be given 200/250 mg po. qd.
Study NCT05472948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab administered IV at a dose of 200mg every 3 weeks.
Study NCT05472948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
Study NCT05809557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy toxicity tool
Description: CARG is an EMR based tool that informs medical oncologists visiting a patient for the first time of potential risk of chemotherapy toxicity. This intervention will make available a simple calculator which includes: Gender, Height and weight, Cancer Subtype, Hemoglobin, How is your hearing (with hearing aid, if needed)?, Number of falls in the past 6 months, Can you take your own medicines, Does your health limit you in walking one block., During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? and Glomerular filtration rate.~The CARG chemotoxicity calculator will be built into the patient navigator and its use will be assessed on a monthly basis and used to inform iteration.
Study NCT05729880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI, MRS
Description: Scan of right calf and thigh
Study NCT05809557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncology Consultation
Description: Oncologists will consult new patient with a new diagnosis of cancer.
Study NCT05809557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oncology Consultation
Description: Oncologists will consult new patient with a new diagnosis of cancer.
Study NCT05109468 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
Study NCT05729880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Scan of right calf and thigh
Study NCT03929315 — intervention group
Intervention type: BEHAVIORAL
Intervention: OLV technique on tracheo-bronchial model
Description: Models will range in size from 6 yrs to 6 weeks.
Study NCT05418023 — intervention group
Intervention type: OTHER
Intervention: Salivary Collection
Description: Collection of saliva via swab for miRNA processing
Study NCT05418023 — intervention group
Intervention type: OTHER
Intervention: Adaptive Assessment
Description: Includes Vineland Adaptive Behavior Scale or equivalent
Study NCT05418023 — intervention group
Intervention type: OTHER
Intervention: Medical and Demographic questionnaire
Description: Survey that collects basic medical and demographic information
Study NCT05418023 — intervention group
Intervention type: OTHER
Intervention: Autism Assessment
Description: Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
Study NCT05418023 — intervention group
Intervention type: OTHER
Intervention: Intellectual Development Assessment
Description: Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
Study NCT06139120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of hypersensitivity
Description: Assessment of pain hypersensitivity in body segments was performed using pressure pain measurement
Study NCT05784038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Viral genomic
Description: Evaluation of mpox viral genomic
Study NCT05784038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Untargeted Metabolomics
Description: Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.
Study NCT06249802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 12-month intake of medication
Study NCT03952494 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomind®Professional PGx Express TM
Description: The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Meal at Cold Temperature
Description: High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Meal at Warm Temperarute
Description: High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Meal at Hot Temperature
Description: High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Meal at Cold Temperature
Description: High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Meal at Warm Temperature
Description: High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Meal at Hot Temperature
Description: High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Meal at Cold Temperature
Description: High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Meal at Warm Temperature
Description: High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
Study NCT05822167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Meal at Hot Temperature
Description: High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
Study NCT05963529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Humidity-ramp protocol
Description: Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
Study NCT05963529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Above-inflection fixed-condition exposure
Description: After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
Study NCT05963529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Below-inflection fixed-condition exposure
Description: After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
Study NCT05963529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control fixed-condition exposure
Description: Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
Study NCT06249802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-month intake of matching placebo
Study NCT06011187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Fluid administration will be given per routine care MAP between 65 - 70 mmHg
Study NCT06011187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFM
Description: AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg